ARTICLE | Company News

Sanofi suit: Merck's follow-on biologic infringes Lantus patents

September 19, 2016 7:00 AM UTC

In a suit filed in federal court, Sanofi (Euronext:SAN; NYSE:SNY) alleged Merck & Co. Inc. (NYSE:MRK) infringed 10 of its patents covering the pharma's Lantus insulin glargine and Lantus SoloStar pen.

Last month, Merck said FDA accepted for filing an NDA for MK-1293 to treat Type I and Type II diabetes. The candidate is a follow-on biologic of Lantus, a synthetic sustained-release subcutaneous insulin analog. ...